TGen News & Press Releases

• Written by Steve Yozwiak /
• Posted Saturday March 5, 2005

TGen's Von Hoff Honored at International Cancer Conference

Amsterdam, Netherlands, March 3, 2005-The Translational Genomics Research Institute (TGen) today announced that Daniel Von Hoff, MD, Director of Translational Drug Development at TGen and the Director of the Arizona Health Sciences Center's Cancer Therapeutics Program is the recipient of the 2005 New Drug Development Organization Honorary Lecture Award for his significant contributions to advancing cancer drug therapy.

"We honor Dr. Von Hoff in recognition of his strong personal commitment and dedication to advancing new treatment options from the laboratory stage to clinical application, providing hope to cancer patients worldwide," said Marinus W. Lobbezoo, PhD, Congress Director of the New Drug Development Organization (NDDO) Research Foundation in Amsterdam.

As part of this award, Dr. Von Hoff will give the Honorary Lecture at the third International Symposium on Targeted Anticancer Therapies (TAT 2005) in Amsterdam. The title of his talk is "Targeting Contextual Vulnerabilities in Cancer".

"On behalf of my staff and colleagues, I am delighted to have been selected to receive this award," said Dr. Von Hoff. "I am also grateful to the NDDO for all its efforts in supporting therapeutic development in the area of cancer, and to those who have supported my work over the years."

The lecture was initially established in the early 1990s as the NDDO Honorary Award, and was a way for NDDO to honor someone who had been instrumental in advancing the NDDO as an oncology drug development institute. Later on, the scope of the award was broadened to include those who have made significant contributions to advancing drug therapy of cancer in general as nominees.

The TAT 2005 meeting will be the next event in the highly successful series of Amsterdam-based meetings on new anticancer drugs. The last two meetings in this series, held in 2002 and 2003, largely focused on signal transduction modulators. The upcoming symposium will cover a broader array of innovative anticancer agents including the most promising ones in preclinical and clinical development. # # #

About TGen
The Translational Genomics Research Institute (TGen) is a not-for-profit organization whose primary mission is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the human Genome Project to apply to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

About the New Drug Development Organization
The New Drug Development Organization (NDDO) also encompasses the NDDO Research Foundation and NDDO Oncology. The NDDO Research Foundation aims at contributing to the drug development process in oncology by the conduct of methodological research and the organization of top-level scientific meetings on specific drug development themes and new approaches to cancer treatment. Thus, NDDO Oncology and the NDDO Research Foundation are two complementary entities operating under the NDDO umbrella, each with its specific mission and range of activities.